Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Eli Lilly and Company stock (LLY)

Buy Eli Lilly and Company stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Eli Lilly and Company is a drug manufacturers - general business based in the US. Eli Lilly and Company shares (LLY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $825.62 – an increase of 3.81% over the previous week. Eli Lilly and Company employs 43,000 staff and has a trailing 12-month revenue of around $40.9 billion.

Our top picks for where to buy Eli Lilly and Company stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

How to buy Eli Lilly and Company stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – LLY. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Eli Lilly and Company stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Crypto alternative
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Eli Lilly and Company stock price (NYSE: LLY)

Use our graph to track the performance of LLY stocks over time.

Eli Lilly and Company shares at a glance

Information last updated 2024-12-04.
Latest market close$825.62
52-week range$558.01 - $970.92
50-day moving average $849.98
200-day moving average $836.95
Wall St. target price$992.82
PE ratio 89.5189
Dividend yield $5.03 (0.64%)
Earnings per share (TTM) $9.27

Is it a good time to buy Eli Lilly and Company stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Eli Lilly and Company price performance over time

Historical closes compared with the close of $829.84 from 2024-12-04

1 week (2024-11-29) 4.34%
1 month (2024-11-06) 6.89%
3 months (2024-09-06) -8.07%
6 months (2024-06-06) -0.89%
1 year (2023-12-06) 40.83%
2 years (2022-12-06) 128.87%
3 years (2021-12-06) 247.06%
5 years (2019-12-06) 639.89%

Is Eli Lilly and Company stock undervalued or overvalued?

Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Eli Lilly and Company's P/E ratio

Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 90x. In other words, Eli Lilly and Company shares trade at around 90x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Eli Lilly and Company's PEG ratio

Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7643. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Eli Lilly and Company's EBITDA

Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.6 billion.

The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.

Eli Lilly and Company financials

Revenue TTM $40.9 billion
Operating margin TTM 39.77%
Gross profit TTM $21.9 billion
Return on assets TTM 13.95%
Return on equity TTM 65.32%
Profit margin 20.48%
Book value $15.83
Market Capitalization $746.3 billion

TTM: trailing 12 months

Eli Lilly and Company share dividends

51%

Dividend payout ratio: 51.13% of net profits

Recently Eli Lilly and Company has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $5.03 per share.

Eli Lilly and Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Eli Lilly and Company's most recent dividend payout was on 9 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 November 2024 (the "ex-dividend date").

Have Eli Lilly and Company's shares ever split?

Eli Lilly and Company's shares were split on a 2:1 basis on 15 October 1997 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.

Eli Lilly and Company share price volatility

Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $558.0081 up to $970.9219. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.43. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).

Eli Lilly and Company overview

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.

Frequently asked questions

What percentage of Eli Lilly and Company is owned by insiders or institutions?
Currently 0.154% of Eli Lilly and Company shares are held by insiders and 83.427% by institutions.
How many people work for Eli Lilly and Company?
Latest data suggests 43,000 work at Eli Lilly and Company.
When does the fiscal year end for Eli Lilly and Company?
Eli Lilly and Company's fiscal year ends in December.
Where is Eli Lilly and Company based?
Eli Lilly and Company's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285
What is Eli Lilly and Company's ISIN number?
Eli Lilly and Company's international securities identification number is: US5324571083
What is Eli Lilly and Company's CUSIP number?
Eli Lilly and Company's Committee on Uniform Securities Identification Procedures number is: 532457108

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site